Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07505303 · ClinicalTrials.gov registry record · Phase 2
MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial
A Phase 2 study, sponsored by Eccogene.
- Active
- Registry status
- Phase 2
- Development phase
- 151
- Enrollment target
NCT07505303: Active Phase 2 study, sponsored by Eccogene.
NCT07505303 is a Phase 2 study that is active but no longer recruiting, run by Eccogene. The registered enrollment target is 151 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07505303, a Phase 2 study, is active but no longer recruiting, sponsored by Eccogene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 151 participants
- Enrollment target
Study Summary
The primary objective of this trial is to evaluate the effect of oral ECC4703 on body weight reduction and in a sub-study on liver fat content as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 20.
Interventions
- DRUG Placebo
- DRUG Semaglutide
- DRUG ECC4703
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2026-03-23 |
| Est. Completion | 2026-10-15 |
| Phase | Phase 2 |
What the registry record for NCT07505303 still lists
NCT07505303 is an interventional study that assigns participants to a tested intervention. The registered 151 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07505303 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07505303 about?
NCT07505303 is a clinical study titled "MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial". The primary objective of this trial is to evaluate the effect of oral ECC4703 on body weight reduction and in a sub-study on liver fat content as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 20.
What is the current status of trial NCT07505303?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 151 participants. The study started on 2026-03-23. Estimated completion is 2026-10-15.
What interventions are being tested in trial NCT07505303?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG), ECC4703 (DRUG).
Who is sponsoring clinical trial NCT07505303?
This trial is sponsored by Eccogene, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07505303's enrollment target sits among peer trials
151 454th of 2000 higher than 1,546 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01409161 · 151 participants · Phase 2
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- NCT04245397 · 151 participants · Phase 1
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
- NCT05761223 · 151 participants · Phase 1
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
- NCT07195656 · 151 participants · NA
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI